Suraksha Diagnostic Ltd

Suraksha Diagnostic Ltd, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 11 Aug 2025. The stock’s recent price action and technical indicators suggest a transition from a sideways trend to a bearish outlook, reflecting growing investor caution amid broader market pressures.

Suraksha Diagnostic Ltd’s shares declined sharply to a new 52-week low of Rs.227.95 on 2 Mar 2026, marking a significant drop amid a five-day losing streak that has seen the stock fall by 6.56%. This decline comes despite a broader market recovery, with the Sensex rebounding after an initial gap down opening.

Suraksha Diagnostic Ltd, a player in the healthcare services sector, has reached a new all-time low price of Rs. 227.95, marking a significant decline amid a period of sustained underperformance relative to the broader market and its sector peers.

Suraksha Diagnostic Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by changes in its price-to-earnings and price-to-book value ratios. This development comes amid a mixed performance backdrop and evolving market sentiment within the healthcare services sector.

Suraksha Diagnostic Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Suraksha Diagnostic Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This change reflects evolving market perceptions amid mixed returns relative to the broader Sensex, highlighting a nuanced investment case for healthcare services investors.

Suraksha Diagnostic Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Suraksha Diagnostic Limited, a Kolkata-based diagnostic services provider, reported a consolidated net profit of ₹8.99 crores for Q2 FY26, marking a sequential decline of 4.36% from ₹9.40 crores in Q1 FY26 and a year-on-year contraction of 13.06% from ₹10.34 crores in Q2 FY25. The company's market capitalisation stands at ₹1,485 crores, positioning it as a small-cap player in India's healthcare services sector. Despite robust revenue growth of 17.95% year-on-year, deteriorating operating margins and elevated interest costs continue to constrain profitability, raising concerns about the sustainability of earnings quality in an increasingly competitive diagnostic landscape.

Suraksha Diagnostic Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 August 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Suraksha Diagnostic Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving investor sentiment amid a competitive healthcare services sector. Despite a recent upgrade in its mojo grade from Sell to Hold, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook compared to its historical averages and peer group benchmarks.

Suraksha Diagnostic Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 11 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 22 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Suraksha Diagnostic Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Suraksha Diagnostic Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Suraksha Diagno., a small-cap player in the Healthcare Services sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. Despite ongoing challenges in stock performance, certain fundamental aspects have prompted a reassessment of the company’s standing among investors and analysts.

Suraksha Diagno., a small-cap player in the Healthcare Services sector, has recently undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical positioning amid a challenging market environment.

Suraksha Diagnostic Limited, a Kolkata-based healthcare diagnostics provider with a market capitalisation of ₹1,669 crores, reported consolidated net profit of ₹8.99 crores for Q2 FY26, declining 4.36% quarter-on-quarter and 13.06% year-on-year. Despite robust revenue growth of 17.95% YoY to ₹78.73 crores, the company witnessed significant margin compression as operating profit margin (excluding other income) contracted to 30.62% from 34.74% in the year-ago quarter. The stock traded at ₹323.90 on November 10, 2025, showing resilience with gains of 10.66% over the past month, though it remains 13.76% lower year-to-date.